Health Economics

  • Defines the ultimate outcome in a trial. Common endpoints are severe toxicity, disease progression or death. These endpoints (other than death) are rarely endpoints of the sort to satisfy economists because they are not easily interpretable in welfare terms and/or because they mark a point in time beyond which further measurement and observation are not done (which may therefore require modelling if there are significant post-endpoint events or trends for cost-effectiveness purposes). From such a perspective, such endpoints plainly are not 'ulti mate'.